JP2024525479A5 - - Google Patents

Info

Publication number
JP2024525479A5
JP2024525479A5 JP2023580719A JP2023580719A JP2024525479A5 JP 2024525479 A5 JP2024525479 A5 JP 2024525479A5 JP 2023580719 A JP2023580719 A JP 2023580719A JP 2023580719 A JP2023580719 A JP 2023580719A JP 2024525479 A5 JP2024525479 A5 JP 2024525479A5
Authority
JP
Japan
Prior art keywords
composition according
composition
medium
sodium phosphate
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023580719A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525479A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/036036 external-priority patent/WO2023278883A1/en
Publication of JP2024525479A publication Critical patent/JP2024525479A/ja
Publication of JP2024525479A5 publication Critical patent/JP2024525479A5/ja
Pending legal-status Critical Current

Links

JP2023580719A 2021-07-02 2022-07-01 細胞性フィブロネクチン組成物を作製及び使用するためのプロセス Pending JP2024525479A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163217952P 2021-07-02 2021-07-02
US63/217,952 2021-07-02
US202163235605P 2021-08-20 2021-08-20
US63/235,605 2021-08-20
PCT/US2022/036036 WO2023278883A1 (en) 2021-07-02 2022-07-01 Processes for making and using a cellular fibronectin composition

Publications (2)

Publication Number Publication Date
JP2024525479A JP2024525479A (ja) 2024-07-12
JP2024525479A5 true JP2024525479A5 (https=) 2025-07-08

Family

ID=84690665

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023580719A Pending JP2024525479A (ja) 2021-07-02 2022-07-01 細胞性フィブロネクチン組成物を作製及び使用するためのプロセス

Country Status (7)

Country Link
US (4) US12187784B2 (https=)
EP (1) EP4363442A4 (https=)
JP (1) JP2024525479A (https=)
KR (1) KR20240070501A (https=)
AU (1) AU2022303345A1 (https=)
CA (1) CA3224150A1 (https=)
WO (1) WO2023278883A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801028A4 (en) 2018-05-30 2022-04-13 Direct Biologics LLC A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use
US12569517B2 (en) 2019-02-07 2026-03-10 Direct Biologics, Llc Method for treating osteoarthritis with mesenchymal stem cell exosomes
US12213995B2 (en) 2019-07-18 2025-02-04 Direct Biologics, Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
KR20230004709A (ko) 2020-04-22 2023-01-06 다이렉트 바이오로직스 엘엘씨 감염성 질환과 연관된 염증성 병태를 치료하기 위한 방법 및 조성물
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728637A (en) 1983-11-04 1988-03-01 Ralph Silverman Complex of macromolecules extracted from mesenchymal cells for treating chronic degenerative disease
JPS61103836A (ja) * 1984-10-24 1986-05-22 Green Cross Corp:The フイブロネクチン製剤
PT84991B (pt) 1986-06-06 1990-03-08 Genentech Inc Processo para a producao de actividador do plasminogenio biologicamente activo
US5750378A (en) * 1991-12-20 1998-05-12 Fibrogenex, Inc. Method for preparing cellular fibronectin
US6372494B1 (en) 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
WO2008020815A1 (en) * 2006-08-15 2008-02-21 Agency For Science, Technology And Research Mesenchymal stem cell conditioned medium
US10214720B2 (en) 2007-06-29 2019-02-26 Makoto Funaki Low rigidity gels for MSC growth modulation
US20110020846A1 (en) * 2009-07-22 2011-01-27 Jau-Song Yu Oral cancer biomarker and inspection method using the same
US9220810B2 (en) * 2010-12-10 2015-12-29 Florida State University Research Foundation, Inc. Mesenchymal stem cells (MSC) expansion methods and materials
US9545370B2 (en) * 2012-05-08 2017-01-17 BioRegenerative Sciences, Inc. Bioactive compositions and methods for their preparation and use
KR101613437B1 (ko) 2014-07-30 2016-04-20 울산대학교 산학협력단 팔라듐 나노덴드라이트―그래핀 나노하이브리드 기반 수소센서 및 그 제조방법
WO2016178586A2 (en) * 2015-05-01 2016-11-10 Auckland Uniservices Limited Collagen compositions and preparation and uses thereof
GB201508931D0 (en) * 2015-05-26 2015-07-01 Univ Glasgow The And Georgia Tech Res Corp Materials and methods for tissue regeneration
EP3655525A4 (en) 2017-07-16 2021-04-21 Ramot at Tel-Aviv University Ltd. STEM CELL SECRETOME FROM HUMAN MUCCOUS

Similar Documents

Publication Publication Date Title
JP2024525479A5 (https=)
JP2022526855A5 (https=)
US9180145B2 (en) Compositions and methods for recruiting and localizing stem cells
JP2599552B2 (ja) 水痘帯状疱疹ウイルスの弱毒ワクチンの製造方法
ES2892974T3 (es) Composiciones que comprenden células madre mesenquimales y usos de las mismas
JP2023521086A5 (https=)
Xu et al. Rosuvastatin treatment activates JAK-STAT pathway and increases efficacy of allogeneic mesenchymal stem cell transplantation in infarcted hearts
US9849168B2 (en) Attenuated live vaccine against mycoplasmal pneumonia of swine (MPS) and use thereof
US10004795B2 (en) Process for preparing an attenuated tetravalent dengue vaccine
Walz et al. Effect of immunization on acute and latent infections of vaginouterine tissue with herpes simplex virus types 1 and 2
WO2021160163A1 (en) Methods for prevention or treatment of virus-induced organ injury or failure with il-22 dimer
JP2023520233A5 (https=)
CN115778987B (zh) 一株可缓解骨质疏松的动物双歧杆菌及其应用
JP2014521742A (ja) 生物学的製品、特にはワクチンの真空保存
JP2024525479A (ja) 細胞性フィブロネクチン組成物を作製及び使用するためのプロセス
JP2020506691A (ja) 新規配合物
CN111249293A (zh) 黄芪甲苷在制备促进血管新生药物中的应用
CN115969885A (zh) 一株可缓解骨质疏松的长双歧杆菌及其应用
CN104928235A (zh) 基于干细胞的组合物及其在制备用于冠心病的制剂中的应用
US11123420B2 (en) Stable live attenuated recombinant dengue vaccine
CN114699404A (zh) 二氢青蒿素在制备促进骨组织再生修复药物中的应用
Summers et al. Does virus persist in the uvea in multiple sclerosis, as in canine distemper encephalomyelitis?
KR20210157065A (ko) 융합 단백질 및 이를 포함하는 코로나바이러스 백신 조성물
KR101885375B1 (ko) 신규한 약독화 prrs 바이러스 균주 및 이를 포함하는 백신 조성물
JP2021521193A5 (https=)